Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-02
2010-10-26
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S422000, C424S551000, C435S455000
Reexamination Certificate
active
07820634
ABSTRACT:
A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. The submucosal tissue component of the present composition comprises the tunica submucosa of vertebrate intestine delaminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.
REFERENCES:
patent: 4902508 (1990-02-01), Badylak et al.
patent: 4956178 (1990-09-01), Badylak et al.
patent: 5275826 (1994-01-01), Badylak et al.
patent: 5281422 (1994-01-01), Badylak et al.
patent: 5352463 (1994-10-01), Badylak et al.
patent: 5372821 (1994-12-01), Badylak et al.
patent: 5439446 (1995-08-01), Barry
patent: 5516533 (1996-05-01), Badylak et al.
patent: 5554389 (1996-09-01), Badylak et al.
patent: 5755791 (1998-05-01), Whitson et al.
patent: 5763416 (1998-06-01), Bonadio et al.
patent: 5962427 (1999-10-01), Goldstein et al.
patent: 6653291 (2003-11-01), Badylak et al.
patent: 2005/0003537 (2005-01-01), Badylak et al.
patent: 92/15676 (1992-09-01), None
patent: 93/19660 (1993-10-01), None
patent: 96/25179 (1996-08-01), None
Agrawal, S., “Antisense Oligonucleotides: Towards Clinical Trials,” Reviews, TIBTECH, vol. 14, 1996, pp. 376-387.
Benvenisty, N., et al., “Direct Introduction of Genes into Rats and Expression of the Genes,” Proc. Natl. Acad. Sci. USA, vol. 83, Dec. 1986, pp. 9551-9555.
Bonadio, J., et al., “Direct Gene Transfer into Skeletal Tissues in Vivo,” Abstracts of Papers Presented at the 1994 Meeting on Gene Therapy, Sep. 21-25, 1994, pp. 185.
Branch, A. D., “A Good Antisense Molecule is Hard to Find,” TIBS 23, Feb. 1998, pp. 45-50.
Culver, K. W., et al., “Gene Therapy for Cancer,” TIG, vol. 10, No. 5, 1994, pp. 174-178.
Dubensky, T. W., et al., “Direct Transfection of Viral and Plasmid DNA into the Liver or Spleen of Mice,” Proc. Natl. Acad. Sci. USA, vol. 81, Dec. 1984, pp. 7529-7533.
Gura, T., “Antisense Has Growing Pains,” Research News, Science, vol. 270, Oct. 27, 1995, pp. 575-577.
Hodgson, C. P., “Advances in Vector Systems for Gene Therapy,” Patent Update, Biologicals & Immunologicals, Exp. Opin. Ther. Patents, vol. 5, 1995, pp. 459-468.
Kaneda, Y., et al. “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver,” Science, Reports, Jan. 1989, pp. 375-378.
Ledley, F. D., “Pharmaceutical Approach to Somatic Gene Therapy,” Pharmaceutical Research, vol. 13, No. 11, 1996, pp. 1595-1614.
Mannino R. J., et al., “Liposome Mediated Gene Transfer,” BioTechniques, vol. 6, No. 7, Jul./Aug. 1988, pp. 682-690.
Marshall, E., “Gene Therapy's Growing Pains,” Science, vol. 269, Aug. 25, 1995, pp. 1050-1055.
Miller, N., et al., “Targeted Vectors for Gene Therapy,” The FASEB Journal, vol. 9, Feb. 1995, pp. 190-199.
Nicolau, C., et al., “In Vivo Expression of Rat Insulin After Intravenous Administration of the Liposome-Entrapped Gene for Rat Insulin I,” Proc. Natl. Acad. Sci. USA, vol. 80. Feb. 1983, pp. 1068-1072.
Niyibizi, C., et al., “Potential Role for Gene Therapy in the Enhancement of Fracture Healing,” Clinical Orthopaedics and Related Research, No. 355S, 1998, 5148-5153.
Orkin, S. H., et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” Dec. 7, 1995, 39 pages.
Seeger, C., et al., “The Cloned Genome of Ground Squirrel Hepatitis Virus is Infectious in the Animal,” Proc. Natl. Acad. Sci. USA, vol. 81, Sep. 1984, pp. 5849-5852.
Stein, C. A., et al., “Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?,” Science, vol. 261, Aug. 20, 1993, pp, 1004-1012.
Verma, I. M., et al., “Gene Therapy—Promises, Problems and Prospects,” Nature, vol. 389, Sep. 18, 1997, pp. 239-242.
Wolff, J. A., et al., “Conditions Affecting Direct Gene Transfer into Rodent Muscle In Vivo,” BioTechniques, vol. 11, No. 4, 1991, pp. 474-485.
Wolff J. A., et al., “Direct Gene Transfer into Mouse Muscle in Vivo,” Science, vol. 247, Mar. 23, 1990, pp. 1465-1468.
Wu-Pong, S., “Oligonucleotides: Opportunities for Drug Therapy and Research,” Pharmaceutical Technology, vol. 18, October 1994, pp. 102-114.
Wu G. Y., et al., “Receptor-Mediated Gene Delivery and Expression in Vivo,” The Journal of Biological Chemistry, vol. 263, No. 29, Oct. 15, 1988, pp. 14621-14624.
Zhu, Y. Y., et al., “Direct Gene Transfer into Regenerating Achilles' Tendon,” 40th Annual Meeting, Orthopaedic Research Society, Feb. 21-24, 1994, pp. 14-3.
Zou, J.T., et al., “Characterization of a Rice Pollen-Specific Gene and Its Expression,” American Journal of Botany, vol. 81, No. 5, 1994, pp. 552-561.
Badylak Stephen F.
Bonadio Jeffrey
Voytik Sherry
Barnes & Thornburg LLP
Clarian Health Partners, Inc.
Falk Anne-Marie
Purdue Research Foundation
The Regents of the University of Michigan
LandOfFree
Composition and method for production of transformed cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for production of transformed cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for production of transformed cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158974